-
UEFA chief Ceferin warns Italy could lose Euro 2032 without stadium improvements
-
Italy's football chief resigns after World Cup disaster
-
Edoardo Molinari named European vice-captain for Ryder Cup
-
'Extraordinary news': Dutch recover stolen gold Romanian helmet
-
France considers reform for New Caledonia
-
UK foreign minister stresses 'urgent need' to reopen Hormuz strait
-
Macron says Trump marriage jibe does not 'merit response'
-
Russia will send second ship with oil to Cuba: minister
-
Belgian bishop takes on Vatican with push to ordain married men
-
Oil rallies, stocks drop as Trump dampens Mideast hopes
-
Nexperia's China unit nears fully local production of chips: company sources
-
Indonesia issues fresh summons for Google, Meta over teen social media ban
-
Japan axe coach Nielsen 12 days after winning Women's Asian Cup
-
French President Macron lands in South Korea after Japan visit
-
India's says defence exports hit 'all-time high' of $4 bn
-
Nielsen leaves as Japan coach weeks after winning Women's Asian Cup
-
Too bright: Seoul to dim digital billboards after complaints
-
Iran vows 'crushing' attacks on US after Trump threats
-
Women's Asian Cup finalists accuse governing body over equal money
-
French president Macron heads to South Korea after Japan visit
-
Armenia's underground salt clinic at centre of alternative medicine debate
-
'Muted' international response as Senegal enacts same-sex relations law
-
Slow boat to Ilulissat: long nights on Greenland's last ferry
-
Wemby rampant again as Spurs rack up 10th straight win
-
Ukrainian death metal band growls against Russia's war
-
Iran fires missiles at Israel after Trump threatens weeks of strikes
-
Surging 'Jewish terrorism' in West Bank condemned but unpunished
-
England's Brook, Bethell warned after New Zealand nightclub incident
-
What's real anymore? AI warps truth of Middle East war
-
Europe to negotiate with NASA on lunar missions: ESA
-
Trump tells US that Iran war victory near, but vows big strikes
-
Poppies offer hope in fire-scarred Los Angeles
-
Trump says Iran war almost over, warns of weeks more heavy strikes
-
Oil rallies, stocks tumble as Trump says US to hammer Iran further
-
US Republicans announce deal to end partial government shutdown
-
Trump tells Americans that Iran war ending as popularity dips
-
7.4-magnitude quake off Indonesia kills one, tsunami warning lifted
-
Bordeaux-Begles' Van Rensburg 'not thinking' about Champions Cup double
-
Valsoft Corporation Strengthens Its Retail Software Portfolio with the Acquisition of NedFox
-
Side-by-Side Conference Hosts Close to 800 Participants in Malta to Advance Women's Health Care
-
U.S. Polo Assn. Supports Division I National Intercollegiate Championship, Showcasing the Future of the Sport of Polo
-
US automakers report mixed sales as car market awaits war impact
-
Astronauts begin NASA lunar mission after climactic blast-off
-
Astronauts blast off for historic US lunar journey
-
Embattled Woods won't captain 2027 Ryder Cup team: PGA of America
-
Judge allows Woods to travel overseas for treatment
-
Chelsea's Bompastor furious as Arsenal reach women's Champions League semis
-
US lifts sanctions on Venezuelan interim leader Delcy Rodriguez
-
Arsenal resist Chelsea rally to reach women's Champions League semis
-
Defending champ Pegula wins WTA Charleston opener
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
F.Pavlenko--BTB